Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $20.6 million.

  • Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1106.39% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 1106.39%. This contributed to the annual value of $18.3 million for FY2024, which is 300.16% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $20.6 million, which was up 1106.39% from $19.9 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $20.6 million for Q3 2025, and its period low was $16.8 million during Q1 2022.
  • In the last 5 years, Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $17.8 million in 2023 and averaged $18.0 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) plummeted by 245.83% in 2022 and then skyrocketed by 1106.39% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $17.2 million in 2021, then dropped by 2.19% to $16.9 million in 2022, then increased by 5.27% to $17.8 million in 2023, then grew by 3.0% to $18.3 million in 2024, then grew by 12.79% to $20.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $20.6 million in Q3 2025, compared to $19.9 million in Q2 2025 and $19.2 million in Q1 2025.